Bifidobacterium breve M-16V

Bifidobacterium breve M-16V is a clinically studied probiotic strain that produces short-chain fatty acids and bacteriocins to support gut health. This strain modulates immune responses through Toll-like receptor pathways and enhances intestinal barrier function in infants and adults.

Origin & History

Bifidobacterium breve M-16V is a probiotic strain isolated from human breast milk. It is cultivated in controlled environments to ensure purity and efficacy. This strain is particularly noted for its role in infant gut health.

Historical & Cultural Context

Bifidobacterium breve M-16V has been used in Japan and other countries for decades to support infant health and is a staple in many probiotic supplements.

Health Benefits

- Promotes healthy gut flora in infants and adults, enhancing digestion. - Supports immune system development in early life, reducing infection risk. - Reduces allergy symptoms by modulating immune responses, improving comfort. - Enhances respiratory health by reducing inflammation, promoting easier breathing. - Supports brain health by producing neurotransmitters, enhancing cognitive function. - Aids in weight management by influencing gut hormones, reducing appetite. - Improves skin health by reducing systemic inflammation, promoting a radiant complexion.

How It Works

Bifidobacterium breve M-16V produces acetate and lactate through carbohydrate fermentation, creating an acidic environment that inhibits pathogenic bacteria. The strain activates regulatory T-cells via dendritic cell interaction and TLR2/TLR4 pathways, promoting anti-inflammatory cytokine IL-10 production. It strengthens intestinal barrier function by upregulating tight junction proteins claudin-1 and occludin.

Scientific Research

Clinical trials have shown its efficacy in improving gut health and reducing allergic symptoms in infants. Meta-analyses support its role in immune system development.

Clinical Summary

Multiple randomized controlled trials involving over 800 infants have demonstrated M-16V's efficacy in preventing necrotizing enterocolitis and reducing infection rates by 40-60%. A 12-week study with 90 allergic infants showed 35% reduction in eczema severity scores compared to placebo. Respiratory health studies in 200+ children demonstrated 25% fewer upper respiratory infections and reduced inflammatory markers including decreased IL-6 levels. Evidence quality is moderate to high for infant applications, with emerging data for adult benefits.

Nutritional Profile

- Produces short-chain fatty acids beneficial for gut health. - High in bifidogenic activity, promoting beneficial bacteria growth. - Contains enzymes that aid in lactose digestion.

Preparation & Dosage

Commonly administered in doses of 1-10 billion CFUs per day. Available in powder or capsule form. Consult a healthcare provider before use.

Synergy & Pairings

Prebiotics, Omega-3 Fatty Acids, Zinc

Safety & Interactions

Bifidobacterium breve M-16V is generally recognized as safe with minimal side effects, occasionally causing mild bloating or gas during initial use. No significant drug interactions have been reported, though immunocompromised patients should consult healthcare providers before use. The strain is considered safe during pregnancy and breastfeeding based on extensive infant safety data. Contraindications include severe acute pancreatitis and central venous catheter presence due to rare bacteremia risk.